When federal regulators last week approved Digene Corp.'s cervical cancer test as a primary screening tool for women over 30, they catapulted what had been a follow-up test into direct competition ...

Digene Corp. of Gaithersburg will pay a New York biotechnology company at least $30.5 million to settle a patent-infringement lawsuit involving technology used in its leading product, the only ...

“Finding a cure for cancer” is synonymous in our society with the ultimate in success. And yet Digene (DIGE $37), which sells a test that could eradicate cervical cancer, meets with tepid enthusiasm ...

Digene has struck a deal with Austin-based Asuragen to sell a diagnostic test under development for cystic fibrosis. Asuragen is seeking regulatory approval for the test, which would be the second on ...

What: Daryl Faulkner, Chief Executive Officer of Digene Corporation (DIGE), will preside over the opening bell in honor of "Cervical Cancer Screening Month." Where: NASDAQ MarketSite - 4 Times Square ...

NEW YORK (CBS.MW) -- Digene shares could get a lift from news that the Gaithersburg, Md., medical products firm said its DNAwithPap test for human papillomavirus has received the recommendation of The ...

NEW YORK, Jan 12 (Reuters) - Digene Corp's new chief executive officer said on Friday the company could not afford to remain "a one-product company" and would aim to disclose a strategy of moving ...

NEW YORK (CBS.MW) -- Digene shares are rising more than 7 percent to $28.10 after the company said its DNAwithPap test, which is used to assess the presence of high-risk human papillomavirus in women ...